MD+DI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Understanding the Testing Behind Drug Delivery Devices

Image courtesy of Andrii Dragan / Alamy Stock Photo IMG_2022-11-22-140820.jpg
Katie Grayson, of EKG Labs, is set to speak about analytical considerations surrounding extractables and leachables testing of drug-delivery devices at BIOMEDevice Silicon Valley.

Drug-delivery devices release a drug product over time into the human body. Depending on whether the product is intended to be submitted as a medical device or as a pharmaceutical drug product, the requirements for extractable and leachable (E&L) testing may differ. E&L testing for medical devices is typically defined as chemical characterization of medical device materials per ISO 10993-18.

An E&L study for pharmaceutical drug products typically follows USP <1663> and <1664> for extractables and leachables associated with pharmaceutical packaging/delivery systems.

Katie Grayson, a general manager at EKG labs, will present an overview E&L studies, comparing and contrasting E&L requirements between pharmaceutical products and medical devices. Key elements regarding E&L study design of drug-delivery products will be discussed. Case studies on the E&L testing of drug-delivery products will be presented, including implantable infusion pumps and prefilled syringes.



Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.